About Us

Working to Unlock the Potential of Cell and Gene Therapy

Cell and gene therapies (CGTs) use modified cells or cellular matter to treat, prevent or cure serious health issues like cancer, genetic disorders, immunodeficiencies, rare diseases, and more.

CGTs have shown potential to replace damaged cells with functional alternatives or to elicit a desired immune response. Despite this great potential, CGTs have proven complex, expensive, and challenging to bring to market, in part because of the logistic hurdles associated with many of these personalized therapies.

Our POCare Platform is shaping a CGT ecosystem to lower costs for innovators, accelerate treatments to market, and expand access for patients.

Orgenesis works to make therapies commercially accessible

An Ecosystem of Innovation

Our POCare Platform is shaping a CGT ecosystem to lower costs, accelerate treatments to market, and expand access for patients.

We have internal development and services centers and global partner locations where we leverage our expertise with highly scalable and cost-effective solutions to advance a pipeline of owned and partnered technologies for point of care production.

Working with us means immediate access to the know-how that has the potential to commercialize therapies and them to the patients who need them.

Learn More
Total Regenerative Medicine Trials
1066
Phase 1
Phase 2
Phase 3

Making Cell & Gene Therapies a Reality

In 2019, there were over 1,000 cell and gene therapy related clinical trials ongoing globally. But most of these biotechnology companies and research institutes lack the expertise to scale their development and manufacturing operations to make them accessible and affordable.

We work to overcome existing challenges of CGT production with process development, manufacturing systems, logistics, and regulatory expertise.

Learn More